BNTC · Benitec Biopharma Inc.
Benitec Biopharma Inc (BNTC)
What's happening
- BNTC is down 0.85% today, trading at $12.82. — Live quote
- Volume today (449) is well below its 3-month average of 125,720. (Finnhub fundamentals)
- Reports earnings on 2026-09-21 (after market close), 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.24 actual vs. $-0.28 estimated (+14.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $529.6M | $613.9M | $557.5M | $489.3M | $497.4M |
| P/E | -12.75 | -13.92 | -13.33 | -12.90 | -14.90 |
| Price/Book | 2.89 | 3.28 | 5.96 | 5.03 | 5.10 |
| EV/EBITDA | -7.41 | -8.81 | -10.13 | -9.40 | — |
| ROE | -22.66% | -23.54% | -44.68% | -38.97% | -34.22% |
| ROA | -22.21% | -23.13% | -43.55% | -38.07% | -31.74% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-06-30; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -20671.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -10.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BNTC
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 |
| Operating income | -$13.6M | -$13.4M | -$9.8M | -$9.8M | -$15.3M | -$10.8M | -$5.8M | -$4.1M |
| Net income | -$11.9M | -$11.8M | -$9.0M | -$8.8M | -$14.5M | -$9.6M | -$5.1M | -$4.3M |
| EPS (diluted) | $-0.24 | $-0.26 | $-0.22 | $-0.21 | $-0.38 | $-0.26 | $-0.18 | $-0.23 |
| EPS (basic) | $-0.24 | $-0.26 | $-0.22 | $-0.21 | $-0.38 | $-0.26 | $-0.18 | $-0.23 |
Balance sheet
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $187.0M | $190.7M | $96.0M | $99.6M | $105.2M | $79.1M | $68.8M | $52.2M |
| Total liabilities | $3.7M | $3.3M | $2.4M | $2.3M | $7.6M | $3.1M | $4.6M | $5.0M |
| Stockholders' equity | $183.3M | $187.4M | $93.6M | $97.3M | $97.6M | $75.9M | $64.2M | $47.2M |
| Total current assets | $186.0M | $189.6M | $95.1M | $98.5M | $104.0M | $78.7M | $68.3M | $51.7M |
| Total current liabilities | $3.3M | $2.8M | $2.0M | $1.8M | $7.0M | $3.1M | $4.6M | $4.9M |
| Cash & equivalents | $184.8M | $188.8M | $94.5M | $97.7M | $103.6M | $78.3M | $67.8M | $50.9M |
| Other current assets | $1.1M | $562.0K | $480.0K | $628.0K | $361.0K | $366.0K | $426.0K | $516.0K |
| Property, plant & equipment | $116.0K | $115.0K | $118.0K | $131.0K | $145.0K | $151.0K | $154.0K | $179.0K |
| Other non-current assets | $12.0K | $11.0K | $20.0K | $28.0K | $35.0K | $42.0K | $56.0K | $62.0K |
| Common stock & paid-in capital | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K |
| Retained earnings | -$260.9M | -$249.0M | -$237.1M | -$228.2M | -$212.0M | -$202.7M | -$195.3M | -$190.3M |
| Accumulated other comprehensive income (loss) | -$952.0K | -$883.0K | -$750.0K | -$839.0K | -$716.0K | -$688.0K | -$993.0K | -$892.0K |
Cash flow
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.5M | -$3.8M | -$3.4M | -$8.2M | -$3.1M | -$7.7M | -$4.6M | -$3.3M |
| Investing cash flow | -$15.0K | -$11.0K | $0 | $0 | -$6.0K | -$12.0K | $0 | $0 |
| Financing cash flow | $506.0K | $98.2M | $0 | $2.7M | $28.2M | $17.9M | $21.7M | $40.1M |
| Free cash flow | -$4.5M | -$3.8M | — | -$8.2M | -$3.1M | -$7.7M | — | -$3.3M |
| Capital expenditures | $15.0K | $11.0K | — | $0 | $6.0K | $12.0K | — | $0 |
| Depreciation & amortization | $14.0K | $14.0K | $13.0K | $41.0K | $13.0K | $14.0K | $25.0K | $68.0K |
| Share-based compensation | $7.6M | $7.4M | $5.2M | $6.1M | $7.7M | $3.1M | $435.0K | $454.0K |
Income statement
| Line item | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $59.0K |
| Operating income | -$41.8M | -$22.5M | -$19.1M | -$17.9M | -$13.6M |
| Net income | -$37.9M | -$21.8M | -$19.6M | -$18.2M | -$13.9M |
| EPS (diluted) | $-1.05 | $-1.22 | $-14.12 | $-37.88 | $-3.23 |
| EPS (basic) | $-1.05 | $-1.22 | $-14.12 | $-37.88 | $-3.23 |
| Operating margin | — | — | — | — | -$23.0K |
| Net margin | — | — | — | — | -$23.5K |
Balance sheet
| Line item | Jun '25 | Jun '24 | Mar '24 | Dec '23 | Sep '23 |
|---|---|---|---|---|---|
| Total assets | $99.6M | $52.2M | — | — | — |
| Total liabilities | $2.3M | $5.0M | — | — | — |
| Stockholders' equity | $97.3M | $47.2M | — | — | — |
| Total current assets | $98.5M | $51.7M | — | — | — |
| Total current liabilities | $1.8M | $4.9M | — | — | — |
| Cash & equivalents | $97.7M | $50.9M | — | — | — |
| Other current assets | $628.0K | $516.0K | — | — | — |
| Property, plant & equipment | $131.0K | $179.0K | — | — | — |
| Other non-current assets | $28.0K | $62.0K | — | — | — |
| Common stock & paid-in capital | $2.0K | $1.0K | — | — | — |
| Retained earnings | -$228.2M | -$190.3M | -$185.5M | -$181.3M | -$174.5M |
| Accumulated other comprehensive income (loss) | -$839.0K | -$892.0K | — | — | — |
Cash flow
| Line item | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$23.6M | -$19.4M | -$18.0M | -$15.9M | -$12.8M |
| Investing cash flow | -$18.0K | -$179.0K | -$1.0K | -$13.0K | -$221.0K |
| Financing cash flow | $70.5M | $68.0M | $16.0M | — | $22.5M |
| Free cash flow | -$23.6M | -$19.6M | -$18.0M | -$15.9M | -$13.1M |
| Capital expenditures | $18.0K | $179.0K | $1.0K | $13.0K | $221.0K |
| Depreciation & amortization | $66.0K | $87.0K | $136.0K | $167.0K | $231.0K |
| Share-based compensation | $17.4M | $830.0K | $452.0K | $870.0K | $634.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BNTC as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-12-23 to 2026-06-29
Recent transactions
- Most recent: BUCHI J KEVIN (Reporting person) — Gift of 51,813 shares on 2026-06-29.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| BUCHI J KEVIN | Reporting person | Gift | 2026-06-29 | 51,813 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 2025-12-29 | 65,800 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-29 | BUCHI J KEVIN | Reporting person | Gift | 51,813 | $0.00 |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 65,800 | $13.44 |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 11,587 | $13.44 |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 14,320 | $13.10 |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 2,516 | $13.10 |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 42,600 | $12.85 |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 7,400 | $12.85 |
| 2025-12-22 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 16,650 | $12.08 |
| 2025-12-22 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 2,892 | $12.08 |
| 2025-12-19 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 13,950 | $11.48 |
| 2025-12-19 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 2,434 | $11.48 |
| 2025-12-18 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 8,700 | $11.24 |
| 2025-12-18 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 1,515 | $11.24 |
| 2025-11-07 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 730,370 | $13.50 |
| 2025-11-07 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 751,111 | $13.50 |
| 2025-03-31 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 9,503 | $12.63 |
| 2025-03-31 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 1,267 | $12.63 |
| 2025-03-31 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 5,057 | $13.22 |
| 2025-03-31 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 670 | $13.22 |
| 2025-03-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 793,800 | $13.00 |
| 2025-03-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 106,200 | $13.00 |
| 2025-03-12 | BUCHI J KEVIN | Director | Gift | 103,626 | $0.00 |
| 2025-03-12 | BUCHI J KEVIN | Director | Gift | 103,626 | $0.00 |
| 2025-02-27 | BUCHI J KEVIN | Director | Option exercise | 51,813 | $3.86 |
| 2024-12-24 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 17,730 | $11.25 |
| 2024-12-24 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 2,288 | $11.25 |
| 2024-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 24,360 | $10.98 |
| 2024-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | Reporting person | Open market purchase | 3,142 | $10.98 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:42 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-06-30 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-05-29 | 8-K | 2026-05-22 | View on SEC.gov → |
| 2026-05-28 | 4 | 2026-05-26 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-02-12 | 8-K | 2026-02-12 | View on SEC.gov → |
| 2026-02-12 | 10-Q | 2025-12-31 | View on SEC.gov → |
| 2026-01-26 | 4 | 2026-01-22 | View on SEC.gov → |
| 2025-12-29 | 4 | 2025-12-23 | View on SEC.gov → |
| 2025-12-22 | 4 | 2025-12-18 | View on SEC.gov → |
| 2025-12-03 | 4 | 2025-12-01 | View on SEC.gov → |
| 2025-12-03 | 4 | 2025-12-01 | View on SEC.gov → |
Recent news
Headlines about BNTC (Benitec Biopharma Inc.). Links open the publisher — we don’t host full articles.
-
Benitec GAAP EPS of -$0.24 beats by $0.04
Seeking Alpha · 2026-05-14 -
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Yahoo Finance · 2026-05-14 -
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Yahoo Finance · 2026-04-28 -
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Yahoo Finance · 2026-03-10 -
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Yahoo Finance · 2026-03-09 -
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Yahoo Finance · 2026-02-23 -
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation
Yahoo Finance · 2026-02-14 -
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Seeking Alpha · 2026-01-31
No headlines in this category right now — try “All”.